NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ADVM Stock Alerts $14.14 -0.52 (-3.55%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$13.84▼$14.8250-Day Range$8.48▼$28.1052-Week Range$6.81▼$29.70Volume109,875 shsAverage Volume252,171 shsMarket Capitalization$293.41 millionP/E RatioN/ADividend YieldN/APrice Target$34.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Adverum Biotechnologies alerts: Email Address Adverum Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside145.2% Upside$34.67 Price TargetShort InterestHealthy4.33% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment1.07Based on 12 Articles This WeekInsider TradingAcquiring Shares$135,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.63 out of 5 starsMedical Sector67th out of 938 stocksBiological Products, Except Diagnostic Industry11th out of 148 stocks 3.5 Analyst's Opinion Consensus RatingAdverum Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.67, Adverum Biotechnologies has a forecasted upside of 145.2% from its current price of $14.14.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.33% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adverum Biotechnologies has recently decreased by 88.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Adverum Biotechnologies is -0.78. Previous Next 2.8 News and Social Media Coverage News SentimentAdverum Biotechnologies has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Adverum Biotechnologies this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for ADVM on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adverum Biotechnologies are expected to remain at ($5.75) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Adverum Biotechnologies Stock (NASDAQ:ADVM)Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Read More ADVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADVM Stock News HeadlinesMarch 28, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)March 28, 2024 | americanbankingnews.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest UpdateMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 24, 2024 | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Shares Gap Down to $14.75March 23, 2024 | americanbankingnews.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) to Post FY2024 Earnings of ($4.90) Per Share, Chardan Capital ForecastsMarch 22, 2024 | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Stock Rating Upgraded by StockNews.comMarch 21, 2024 | markets.businessinsider.comPositive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial PositionMarch 21, 2024 | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) PT Lowered to $2.00March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 20, 2024 | finance.yahoo.comAdverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial AdjustmentsMarch 20, 2024 | americanbankingnews.comChardan Capital Reaffirms Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM)March 19, 2024 | finance.yahoo.comIs Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?March 19, 2024 | markets.businessinsider.comAdverum Biotechnologies (ADVM) Receives a Buy from TD CowenMarch 18, 2024 | investorplace.comADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023March 18, 2024 | globenewswire.comAdverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesMarch 17, 2024 | seekingalpha.comADVM Adverum Biotechnologies, Inc.March 6, 2024 | finance.yahoo.comADVM Apr 2024 5.000 callMarch 6, 2024 | investorplace.comTurn Pocket Change into Profit: 3 Penny Stocks Ready to PopFebruary 28, 2024 | globenewswire.comAdverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | investorplace.comStocks on the Launchpad: The Next 3 Market SensationsFebruary 25, 2024 | msn.comAdverum Biotechnologies (ADVM) Price Target Increased by 10.53% to 4.28February 22, 2024 | benzinga.comAdverum Biotechnologies Stock (NASDAQ:ADVM), Short Interest ReportFebruary 22, 2024 | investorplace.comUnleash Massive Returns With These 3 Top Penny StocksFebruary 15, 2024 | finance.yahoo.comADVM Feb 2024 4.000 callFebruary 13, 2024 | finance.yahoo.comADVM Sep 2024 2.500 putFebruary 12, 2024 | finance.yahoo.comAdverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 9, 2024 | uk.investing.comAdverum Biotechnologies Inc (ADVM)See More Headlines Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADVM CUSIPN/A CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees121Year FoundedN/APrice Target and Rating Average Stock Price Target$34.67 High Stock Price Target$60.00 Low Stock Price Target$4.00 Potential Upside/Downside+145.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($11.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,170,000.00 Net MarginsN/A Pretax Margin-3,284.53% Return on Equity-98.65% Return on Assets-52.85% Debt Debt-to-Equity RatioN/A Current Ratio4.13 Quick Ratio4.13 Sales & Book Value Annual Sales$3.60 million Price / Sales81.50 Cash FlowN/A Price / Cash FlowN/A Book Value$8.26 per share Price / Book1.71Miscellaneous Outstanding Shares20,750,000Free Float19,655,000Market Cap$293.41 million OptionableOptionable Beta0.88 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Laurent Fischer (Age 60)President, CEO & Director Comp: $1.02MMs. Linda M. Rubinstein M.A. (Age 57)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $940.99kMs. Dena HouseChief People OfficerMs. Carla FiankanSenior Vice President of Regulatory AffairsMr. Michael SteelSenior Vice President of QualityMr. Heikki JouttijarviSenior VP of Manufacturing & Supply Chain Management and Head of Technical OperationsMr. Anand Reddi (Age 41)VP and Head of Corporate Strategy & External Affairs & Engagement Dr. Bill Tan Pharm.D.Senior VP & Head of Global Clinical OperationsDr. Kalliopi Stasi M.D.Ph.D., Senior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsFennec PharmaceuticalsNASDAQ:FENCAura BiosciencesNASDAQ:AURAPoseida TherapeuticsNASDAQ:PSTXBlack Diamond TherapeuticsNASDAQ:BDTXSOPHiA GENETICSNASDAQ:SOPHView All CompetitorsInsiders & InstitutionsTwin Focus Capital Partners LLCBought 100,000 shares on 3/5/2024Ownership: 0.099%Newtyn Management LLCSold 201,904 shares on 2/15/2024Ownership: 0.815%Citadel Advisors LLCBought 2,500 shares on 2/15/2024Ownership: 0.000%AIGH Capital Management LLCBought 1,848,834 shares on 2/12/2024Ownership: 3.140%Worth Venture Partners LLCBought 452,678 shares on 2/9/2024Ownership: 0.776%View All Insider TransactionsView All Institutional Transactions ADVM Stock Analysis - Frequently Asked Questions Should I buy or sell Adverum Biotechnologies stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADVM shares. View ADVM analyst ratings or view top-rated stocks. What is Adverum Biotechnologies' stock price target for 2024? 3 brokerages have issued 12 month price objectives for Adverum Biotechnologies' stock. Their ADVM share price targets range from $4.00 to $60.00. On average, they expect the company's share price to reach $34.67 in the next twelve months. This suggests a possible upside of 145.2% from the stock's current price. View analysts price targets for ADVM or view top-rated stocks among Wall Street analysts. How have ADVM shares performed in 2024? Adverum Biotechnologies' stock was trading at $7.5280 at the beginning of 2024. Since then, ADVM stock has increased by 87.8% and is now trading at $14.14. View the best growth stocks for 2024 here. Are investors shorting Adverum Biotechnologies? Adverum Biotechnologies saw a drop in short interest in March. As of March 15th, there was short interest totaling 648,500 shares, a drop of 88.1% from the February 29th total of 5,430,000 shares. Based on an average trading volume of 231,700 shares, the days-to-cover ratio is currently 2.8 days. Currently, 4.3% of the shares of the stock are sold short. View Adverum Biotechnologies' Short Interest. When is Adverum Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ADVM earnings forecast. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings results on Monday, March, 18th. The biotechnology company reported ($2.30) EPS for the quarter, beating analysts' consensus estimates of ($2.80) by $0.50. When did Adverum Biotechnologies' stock split? Shares of Adverum Biotechnologies reverse split on Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO? 3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA). Who are Adverum Biotechnologies' major shareholders? Adverum Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (4.51%), AIGH Capital Management LLC (3.14%), Newtyn Management LLC (0.81%), Worth Venture Partners LLC (0.78%), Dimensional Fund Advisors LP (0.19%) and Twin Focus Capital Partners LLC (0.10%). Insiders that own company stock include Brigit Riley, Dawn Svoronos, James Paul Scopa, Julie Clark, Laurent Fischer, Peter Soparkar, Richard Beckman, Rupert D'souza and Setareh Seyedkazemi. View institutional ownership trends. How do I buy shares of Adverum Biotechnologies? Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADVM) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.